ANTIOXIDANTS & REDOX SIGNALING
Volume 10, Number 11, 2008
Â© Mary Ann Liebert, 
DOI: 10.1089/ars.2008.2120




                        Forum Original Research Communication

              Role Multifunctional DNA Repair            Redox Signaling Protein Ape1/Ref-1 Cancer             Endothelial Cells: Small-Molecule Inhibition                         Redox Function Ape1

                     Meihua Luo,1 Sarah Delaplane,2 Aihua Jiang,3 April Reed,1 Ying 1
                     Melissa Fishel,1 Rodney L. Nyland II,5 Richard F. Borch,5 Xiaoxi Qiao,3
                                 Millie M. Georgiadis,2 Mark R. Kelley1,2,4,6




Abstract
 DNA base excision-repair pathway responsible repair DNA damage caused oxidation/alky-
lation protects cells effects endogenous exogenous agents. Removal damaged base
creates baseless (AP) site. AP endonuclease1 (Ape1) acts site continue BER-pathway repair. Fail-
ure repair baseless sites leads DNA strand breaks cytotoxicity. addition repair role Ape1, functions major redox-signaling factor reduce activate transcription factors AP1, p53,
HIF-1, control expression genes important cell survival cancer promotion progression.  Ape1 protein interacts proteins involved DNA repair, growth-signaling path-
ways, pathways involved tumor promotion progression. knockdown studies siRNA informative studying role Ape1 normal cancer cells, knocking Ape1 does reveal individual role redox repair functions Ape1. identification small-molecule 
hibitors specific Ape1 functions critical mechanistic studies translational applications. dis-
cuss small-molecule inhibition Ape1 redox effect cancer endothelial cells. Antioxid. 
dox Signal. 10, 1853â€“1867.


Introduction                                                     enine. Ogg1, Nth1, NEIL1, NEIL2 recognize remove
                                                                 purine pyrimidine oxidative DNA-damaged

T    DNA BASE EXCISION-REPAIR (BER) pathway respon-
     sible repair DNA caused oxidative, alkyla-
tion, ionizing radiation protects cells                                                                  adducts. glycosylases require pro-
                                                                 cessing initiating step BER pathway Ape1
                                                                 (Fig. 1). Ape1 (apurinic/apyrimidinic endonuclease 1) toxic effects endogenous exogenous agents.         major repair protein abasic sites, accounting 95  moval incorrect damaged base DNA glycosy-         AP endonuclease activity (77). cleaves 5 abasic
lase, simple glycosylase methylpurine       site generating normal 3-hydroxyl group abasic
DNA glycosylase (MPG AAG) complex glycosylase            deoxyribose-5-phosphate, processed subsequent
(Ogg1, Nth1, NEIL1, ) composes step BER     enzymes BER pathway. removal damaged
pathway (Fig. 1). MPG repairs alkylated DNA major cy-        base results AP site  repaired, result totoxic lesion, 3-methyladenine (3  functions      block DNA replication genetic instability (77). DNA cleave major product lipid oxidation; 1,N(6)-ethenoad-   polymerase  recruited abasic site Ape1 

  1Department Pediatrics (Section Hematology/Oncology), Herman B Wells Center Pediatric Research, 2Department Bio-

chemistry & Molecular Biology, 3Department Ophthalmology, 4Department Pharmacology & Toxicology, Indiana University
School Medicine, Indianapolis, Indiana.
  5Department Medicinal Chemistry Molecular Pharmacology Cancer Center, Purdue University, West Lafayette, Indiana.


                                                            1853
 1854                                                                                                             LUO ET AL.




FIG. 1. Oxidative alkylation DNA damage effectively repaired DNA BER pathway. sim-
plified drawing DNA BER pathway. detailed discussion, Fishel et al. (21).   Damaged bases  case N3-adenine) removed glycosylases result baseless apurinic (AP) sites. Ape1 acts AP sites, pro-
duces nick allows Ã‰-polymerase insert correct base DNA ligase connect DNA backbone. (B) ad-
dition repair function, Ape1 serves redox factor maintaining transcription factors active reduced state. example targets shown.  protection Ape1 DNA damage twofold: directly DNA-repair function indirectly redox activity enabling transcription factors bind DNA 
spond DNA damage. Lack Ape1 activity lead cell death.




use 3OH substrate removed 5 
oxyribose phosphate terminus. DNA ligase ligates remaining break phosphodiester backbone, complet-
ing repair. enzymatic repair activities associated Ape1 include 3-repair diesterase phosphatase ac-
tivity (62), important repair DNA damaged  3-5 exonuclease activity, reported play role excision deoxyribonucleoside analogues (7â€“10).
    Ape1 major cellular function:
Ape1 functions reductionâ€“oxidation (redox) factor stimulates DNA-binding activity numerous transcrip-
tion factors involved cancer promotion pro-
gression, AP-1 (Fos/Jun), NF-B, PAX, HIF-1, HLF,
p53, (Fig. 1) (16, 21, 71). redox function Ape1 mammals vertebrates, demonstrated lack redox function ze-
brafish Ape1 (zApe1) (Fig. 2). acquisition redox
function Ape1 proteins discussed recent publica-      FIG. 2. Comparison selected Ape1 family members
tion (25). molecularly distinct functional domains   bacteria mammals. percentage displayed rep- Ape1, redox repair, completely independent         resents amino acid similarity respective pro- function  e., mutations cysteine position 65   tein human Ape1. mammals acquired 
Cys65 (C65) removes redox function does affect       dox function.
 REDOX ROLE APE1 CANCER ENDOTHELIAL CELLS                                                                           1855
 repair function (Fig. 3), mutation variety     alkylating oxidative DNA-damaging agents
amino acids required DNA repair activity, His309       (19â€“21, 30, 44â€“47, 51, 70, 75, 81). Finally, blocking activ-
(H309) (51) (Fig. 3) does affect redox func-    ity Ape1 lead increase tumor cell
tion]. DNA-repair active site Ape1         killing (37, 68, 73).
clearly delineated (26), redox domain region ob-        use antisense methods cancer cells 
vious. appears required Cys redox        moves repair function Ape1, 
function Cys65, buried Ape1 protein         dox function proteinâ€“protein interactions mediated
(Fig. 3). recently confirmed Georgiadis        Ape1. Ape1 thought interact large number workers (25) mutated Thr (T) zebrafish           repair-related proteins including Ogg1 (66), DNA gly-
Ape1 located position Cys mammalian          cosylases, DNA polymerase  (61), x-ray cross-complement-
Ape1s Cys, subsequent protein gained redox            ing-1 (XRCC1) (4, 53, 61), proliferating cell nuclear antigen
function (25).                                                     (PCNA) (14), Cockayne syndrome B (CSB) (78), flap 
   Interestingly, zebrafish crystal structure quite simi-   donuclease 1 (FEN1) (14, 61, 64).
lar human Ape1, seven Cys            Additional functions ascribed Ape1 mammalian Ape1s structurally conserved.           complicate analysis siRNA. example, conserved Cys65 Cys138 (25). evolution-         implicated nucleotide incision repair (NIR) (76), involved
ary analysis Cys residues vertebrates suggests       NK cellâ€“mediated killing granzyme (GzmA) presence Cys65 distinguishes mammalian            (17, 50), prevents oxidative stress negatively regulating
nonmammalian vertebrate sequences (25).                            Rac1/GTPase activity(60), regulates endothelial pro-
   importance Ape1 cell demonstrated       duction vascular tone (38), recent finding fact possible generate animal knock-    important studies, Ape1 appears suppress model. Ape1 mouse knockouts embryonic lethal            activation PARP1 [poly (ADP-ribose) polymerase 1] dur-
days E5 E9, viable cell lines established      ing repair process oxidative DNA damage, completely deficient Ape1 (79). Previously,         allow cells avoid cell death (63). findings rela-
small number studies using DNA antisense methods           tion Ape1 Bcl2 levels (39) acting neg-
implicated Ape1 cellular resistance variety agents      ative regulator parathyroid hormone gene (6, 16, 59, 74). using antisense Ape1, hypersensitivity      shown (1, 11, 42, 58). Finally, recent data link Ape1 human HeLa, rat glioma, human lung carcinoma cells           PTEN (18), major tumor suppressor impli-
alkylating oxidative agents ionizing radiation      cated playing crucial role variety cancers,  UV radiation indicated (16). recently,          cluding brain tumors (5).
similar enhanced sensitivity osteogenic sarcoma cells           using antisense RNA similar technology, DNA-damaging agents reported (75). Cells lacking          possible determine precisely role 
Ape1 activity hypersensitive alkylating agents      donuclease redox function Ape1 cancer normal
duce formation AP sites (13, 24). Targeted reduction        cells specific inhibitors function indepen- Ape1 protein specific anti-sense oligonucleotides ren-       dently.  long-term goal developing 
ders mammalian cells hypersensitive methylmethane sul-          cer therapeutic agents, small-molecule inhibitors
fonate (MMS), H2O2, bleomycin, temozolomide (TMZ),             major functions Ape1, present data gemcitabine (2, 32, 43, 59, 74). Additionally, blocking     characterizing Ape1 redox mechanism action pair function Ape1 led enhanced effectiveness         demonstrating role redox function Ape1 
DNA-damaging agents temozolomide (TMZ),                cer retinal endothelial cells (RECs) survival 


FIG. 3. Cartoon major amino acids
involved DNA repair redox
function Ape1.   Seven cysteines ex-
ist Ape1, Cys65 appears involved redox activity. Cys
residues, Cys65 unique mammals
(25). lower left panel (B) shows rel-
ative positions seven Cys residues ribbon rendering Ape1. lower
right panels demonstrate Cys65 buried residue. atoms Ape1 shown van der Waals surface render-
ing (C), C65 green P112 red. (D) molecular surface rendering
colored way orientation (C). Cys 65 visible surface accessible  e., buried).  interpretation refer-
ences color figure legend, reader referred web version article www.liebertonline.com/ars).
 1856                                                                                                                 LUO ET AL.

growth using specific small-molecule inhibitor just       (1:9 EtOAc/hexanes), tetramethoxytoluene product redox function Ape1. Inhibition redox function      collected yellow oil (2.27 g, 88 ). Rf  0.57 (7:13
blocks endothelial cell growth blocks growth tu-       EtOAc:hexanes); 1H NMR (CDCl3):  2.43 (s, 3H); 3.74 (s, 3H);
mor cell lines single agent. effect independent   3.89 (s, 3H); 3.92 (s, 3H); 4.00 (s, 3H); 10.41 (s, 1H). Ape1 DNA-repair function.                                        According procedure Ohkawa et al. (57), tetram-
                                                                  ethoxytoluene (0.690 g, 3.25 mmol) dissolved CH2Cl2
Materials Methods                                             (2.0 ml) flame-dried 25-ml round flask                                                                   cooled 0Â°C. ,-Dichloromethyl methyl ether (0.85 ml, 9.6
Synthesis E3330, 3-[5-(2,3-dimethoxy-6-methyl-1,4-
                                                                  mmol) added 0Â°C, followed TiCl4 (1 M benzoquinoyl)]-2-nonyl-2-propionic acid
                                                                  CH2Cl2, 9.0 ml, 9.0 mmol) 0Â°C. reaction warmed
   Reagents used received commercial sources.        slowly room temperature stirred 6 h argon.
THF CH2Cl2 distilled use, acetone         reaction poured chilled water stirred
dried activated 4-Ã… molecular sieves 2 h ar-       10 min. reaction diluted EtOAc, washed
gon. Flash chromatographic separations performed          brine, dried MgSO4, filtered, condensed. using 32- 63-m silica gel; layer chromatography      crude oil purified flash chromatography (3:17
performed Analtech 250-m GHLF plates 254-nm            EtOAc:hexanes) provide 3 (0.696 g, 89 ) yellow oil.
fluorescent indicator. 1H-NMR spectra obtained        Rf  0.26 (3:17 EtOAc:hexanes); 1H NMR (CDCl3):  2.44 (s, Bruker 300-MHz NMR equipped multinuclear (1H,            3H); 3.74 (s, 3H); 3.89 (s, 3H); 3.92 (s, 3H); 4.00 (s, 3H); 10.24
13C, 19F, 31P) 5-mm probe. 1H spectra calibrated      (s, 1H).
CHCl3 7.24 ppm. 13C NMR calibrated CHCl3 77.0
ppm. Elemental analyses performed Purdue Uni-         Ethyl (E)-3-(6-methyl-2,3,4,5-tetramethoxyphenyl)-2-
versity Microanalysis Laboratory Dr. Daniel Lee.               nonylpropenoate (4)
                                                                     following modification procedure Shinkawa
1,2,3,4-Tetramethoxybenzene (2)
                                                                  et al. (55), NaH (0.24 g, 10.0 mmol) added flame-
   following modified procedure Tremblay et al. (72),     dried 50-ml neck round flask connected 2,3,4-trimethoxybenzaldehyde 1 (6.08 g, 31.0 mmol) dis-       water-jacketed reflux condenser. flask purged solved MeOH (60 ml), H2SO4 (0.6 ml) 35            argon, drying tube attached  THF (15
aq. H2O2 (4.0 ml, 40 mmol) added room tempera-            ml) added flask, followed triethyl 2-phospho-
ture. reaction heated reflux 2 h.      noundecanoate (1.90 g, 5.44 mmol) dissolved THF (5 ml)
lution cooled extracted ethyl acetate. lay-      room temperature. reaction heated reflux
ers separated, organic layer washed         30 min, aldehyde 3 (1.04 g, 4.32 mmol) dis-
brine, dried MgSO4, filtered. Flash chromatogra-         solved THF (8 ml) added slowly reflux. 
phy (1:4 EtOAc:hexanes) gave 2,3,4-trimethoxyphenol (5.56         action stirred 3 h reflux g, 98 ) light-red oil. Rf  0.29 (1:4 EtOAc:hexanes); 1H     cooled, acidified dilute HCl, diluted ethyl acetate,
NMR (CDCl3):  3.79 (s, 3H); 3.87 (s, 3H); 3.94 (s, 3H); 5.34     washed brine. organic layer dried
(bs, 1H, OH); 6.57 (q, 2H).                                       (MgSO4), filtered, condensed. resulting oil pu-
   intermediate phenol (3.85 g, 20.9 mmol) dissolved      rified flash-column chromatography (3:17 EtOAc:hexa- dry acetone (90.0 ml), K2CO3 (9.36 g, 67.7 mmol)       nes) provide 4 (1.28 g, 68 ) colorless oil. Rf  0.40
added, followed MeI (9.0 ml, 140 mmol). reaction           (3:17 EtOAc:hexanes); 1H NMR (CDCl3):  0.84 (t, 3H); 1.08
mixture heated reflux 26 h, cooled room          â€“ 1.22 (m, 11H); 1.24 â€“ 1.35 (m, 3H); 1.33 (t, 3H); 2.03 (s, 3H);
temperature, filtered. solvent removed          2.12 (m, 2H); 3.69 (s, 3H); 3.78 (s, 3H); 3.88 (s, 3H); 3.93 (s,
reduced pressure, residue taken CH2Cl2          3H); 4.25 (q, 2H); 7.37 (s, 1H).
(50 ml). suspension filtered, dried MgSO4, fil-
tered  condensed. crude product purified        (E)-3-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4- flash chromatography (1:4 EtOAc:hexanes)          dienyl)-2-nonylpropenoic acid (5)
crystallization Et2O/hexanes provide 2 (3.41 g, 82 )
                                                                     Ester 4 (1.57 g, 3.60 mmol) dissolved EtOH (12 ml), white needles, mp  86â€“87Â°C (Lit. 87â€“87.5Â°C) (3). 1H NMR
                                                                  KOH (0.41 g, 7.3 mmol) added. solution
(CDCl3):  3.80 (s, 6H); 3.88 (s, 6 H); 6.56 (s, 2H).
                                                                  heated reflux stirred 30 min. reaction                                                                   cooled, acidified HCl, extracted ethyl ac-
6-Methyl-2,3,4,5-tetramethoxybenzaldehyde (3)
                                                                  etate. organic layer washed brine, dried    following modified procedure Hansen et al. (28),       MgSO4, filtered, condensed. resulting acid tetramethoxybenzene 2 (2.40 g, 12.1 mmol) added          used following reaction purification. Alter-
100-ml flame-dried round flask THF (50 ml)        natively, product purified flash chromatogra- added. solution cooled 0Â°C, n-BuLi (2.5        phy (2:3 Et2O:hexanes 0.5  AcOH) provide free acid
M hexanes, 6.0 ml, 15 mmol) added slowly 0Â°C.           (1.43 g, 97 ) colorless oil: Rf  0.36 (2:3 Et2O:hexanes solution stirred 1 h 0Â°C; MeI (1.2 ml, 19.3   0.5  AcOH).1H NMR (CDCl3):  0.84 (t, 3H, J  6.9 Hz); 1.13
mmol) added slowly, reaction stirred 0Â°C       (m, 12H); 1.36 (m, 2H); 2.04 (s, 3H); 2.14 (m, 2H); 3.70 (s, 3H);
2 h, reaction mixture warmed room temper-          3.79 (s, 3H); 3.89 (s, 3H); 3.93 (s, 3H); 7.54 (s, 1H).
ature stirred additional hour. reaction acid-         following modifications procedures Shinkawa
ified dilute HCl, washed twice brine, dried        et al. Flader et al. (23, 56), crude acid obtained ear-
MgSO4, filtered, condensed. flash chromatography        lier (1.13 g, 2.77 mmol) dissolved ethyl acetate (15.0
 REDOX ROLE APE1 CANCER ENDOTHELIAL CELLS                                                                             1857

ml) room temperature; HNO3 (1.5 ml) AcOH (6               transfected control pcDNA vector plasmid,
drops) added, reaction stirred 4 h.          pcDNA-wtApe1 redox mutant, pcDNA-C65A, mixture diluted EtOAc (20 ml) washed               Renilla luciferase control reporter vector pRL-CMV (Promega
brine, dried MgSO4, filtered, condensed. red             Corp., Madison, WI) 10:1 ratio using lipofectamine
oil purified flash column chromatogra-             TM 2000. 24-h transfection, cells lysed, phy (2:3 Et2O/hexanes, 0.5  AcOH) recrystallization           Firefly Renilla luciferase activities assayed using
Et2O/hexanes afford 5 (0.443 g, 42 ) red solid; mp           Dual Luciferase Reporter Assay (Promega Corp.)
56â€“57Â°C (Lit. 68Â°C) (56). Elemental analysis: calc C, 66.65 ,         Renilla luciferase activity normalization 96 H, 7.99 ; C, 66.32 , H, 7.89 . 1H NMR (CDCl3):                 microtiter plate luminometer (Thermolabs Systems,
0.84 (t, 3H), 1.18 (bs, 14H); 1.39 (bs, 2H); 1.94 (d, 3H); 2.09 (t,   Franklin, MA). transfection experiments 
3H); 3.99 (s, 3H); 4.02 (s, 3H); 7.26 (d, 1H).                        formed triplicate repeated 3 times inde-
                                                                      pendent experiments.
Expression purification proteins
                                                                         Ape1 transactivation mutation assays. stable Skov-3X
  Proteins purified previously described (25, 29, 36,         ovarian cancer cell line NF-B-Luc gene (luciferase gene
40, 80).                                                              NF-Bâ€“responsive promoter) established                                                                       transfecting Skov-3X cells plasmid pNF-B-Luc (Strat-
Ape1 DNA repair assays                                                agene) using lipofectamine TM 2000 (Invitrogen Life
  Oligonucleotide gel-based Ape1 endonuclease activity             Technologies) screening luciferase-positive colonies
says performed previously described (20, 41).             using Luciferase Assay Kit (Promega Corp.). stable
base excision repair (BER) pathway analysis performed             Skov-3X cells NF-B-Luc gene cotransfected described (67).                                                    plasmid pcDNA-wtApe1 redox mutant pcDNA-
                                                                      C65A Renilla luciferase control reporter vector pRL-
                                                                      CMV (Promega Corp.) 1:10 ratio using lipofectamine
Redox assays
                                                                      TM 2000. analysis conducted described earlier
   Electrophoretic mobility shift assay (EMSA). EMSAs            E3330 studies.
performed described (15) following modifica-
tions. 10-g/l purified Ape1 protein reduced            Cell survival/killing assays
1.0 mM DTT 370C 10 min diluted PBS buffer yield final concentrations 2 g/l protein 0.2 mM                 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymeyhoxyphenyl)-
DTT. l reduced Ape1 protein added EMSA                 2-(4-sulfophenyl)-2H-tetrazolium (MTT) dye assay cell
reaction buffer [10 mM Tris (pH 7.5), 50 mM NaCl, 1 mM                growth performed previously published (20, 75).
MgCl2, 1 mM EDTA, 5  (vol/vol) glycerol] 6 g nu-
clear extract (treated 0.01mM diamide 10 min)           Murine retinal endothelial cell isolation culture
Hey-C2 cells source AP1 protein total volume              Mouse retinal vascular endothelial cells (RVECs) iso- 18 l incubated 30 min. room temperature.               lated described modifications (69). brief, l poly(dI-dC)  poly(dI-dC) (1g/ul) (Amersham Bio-              retinal tissues young adult wild-type mice carrying sciences, Piscataway, NJ) added 5 min followed             SV40 transgene Charles River Laboratories (Im-
1 l 5 hexachloro-fluorescein phosphoramidite                 mortoMouse) digested 0.2 mg/ml collagenase
(HEX)-labeled double-stranded oligonucleotide DNA                 type (Worthington, Lakewood, NJ) DMEM 37Â°C 3
Midland Certified Reagent Company, Midland, TX)                   h. titration filtration 40-m nylon mem-
taining AP-1 consensus sequence (5CGCTTGAT-                      brane (Fisher Scientific, Hanover Park, , dissociated
GACTCAGCCGGAA-3) (0.1 pmol), mixture                     cells incubated sheep anti-rat magnetic beads (Dy- incubated 30 min room temperature. final           nal Biotech, Lake Success, NY) precoated rat anti-
concentration DTT redox reactions 0.02 mM.              mouse PECAM-1 monoclonal antibody (BD Biosciences, San
Samples loaded 5  nondenaturing polyacry-                   Jose, CA) affinity binding 4Â°C 45 min. Bead-bound
lamide gel subjected electrophoresis 0.5X TBE               cells separated magnetic force, plated 24 buffer (200 V 1 h 4Â°C) detected using Hi-           plate precoated 2 g/ml human fibronectin (BD Bio-
tachi FMBio II Fluorescence Imaging (Hitachi Genetic           sciences, San Jose, CA) grown endothelial growth
Systems, South San Francisco, CA). HEX fluorophore             media (EBM-2MV, Cambrex). Cells allowed grow
excited solid-state laser 532 nm (Perkin-Elmer)           beads reaching confluence 10 days 
emits fluorescent light signal 560 nm, mea-        ing assays.
sured using 585-nm filter.
                                                                      Cell-proliferation assay
  Transactivation assay
                                                                         Equal numbers RVECs seeded 2,000 cell    E3330 assays. SKOV-3X Hey-C2 ovarian cancer cell               96 plate. Cells cultured 10
lines transfected NF-B-Luc AP-1-Luc              ng/ml recombinant mouse basic fibroblast growth factor
genes (luciferase gene NF-B AP-1 responsive              (bFGF; R&D Systems, ) supplement various concen-
promoter) using plasmid pNF-B-Luc pAP-1-Luc                    trations E3330 (10, 25, 50, 100 M). group consisted
(Stratagene, La Jolla, CA) lipofectamine TM 2000 (Invit-          wells (n  5) including vehicle control group.
rogen Life Technologies, Carlsbad, CA). cells             days seeding, total number cells 
 1858                                                                                                              LUO ET AL.

sayed using CellTiter 96 AQueous Solution             methyl-1,4-benzoquinoyl)]-2-nonyl-2-propionic acid (E3330)
(Promega Corporation). proliferation rate calculated     (82). molecule previously shown block Ape1
according manufacturerâ€™s instructions. Proliferations      function studies NF-B (35) hematopoietic
RVECs different groups compared ve-           cells (82) specific Ape1 high binding
hicle control group statistical significance.                affinity specificity (34, 65). continue studies,
                                                                 E3330, commercially available, syn-
Tube-formation assay                                             thesized using new approach, developed                                                                  described Methods section. route developed
   Matrigel (BD Biosciences, Bedford, MA) used coat
                                                                 encountering difficulties previously reported (50 l) precooled 96 plate. RVECs 5,000
                                                                 synthetic route (22, 23, 55). result synthesis cells seeded incubated EBM 1 
                                                                 shown Fig. 5.
FBS 10-ng/ml bFGF 37Â°C 24 h. formation                                                                     using E3330 series EMSA experiments, dem-
capillary-like structures RVECs Matrigel quan-
                                                                 onstrate E3330 blocks redox function Ape1 tified counting number closed tube units                                                                  AP-1 downstream target vitro (Fig. 6A)  percentage tube formation vehicle 
                                                                 treatment ovarian cancer cells E3330 (Fig.
trol group calculated E3330 (1, 5, 20 M) treated
                                                                 6B). Additionally, demonstrate E3330 blocks Ape1
group (n  3).
                                                                 redox activity HIF-1 demonstrating redox 
                                                                 hibition specific downstream target (Fig. 6C).
Results
                                                                 Similar results NF-B EMSA studies    number studies implicated Cys65 redox        observed (data shown).
function Ape1.  disagreement exists           E3330 blocked redox function Ape1, Cys Cys involved, just major     effect Ape1 repair endonuclease activity (Fig. 7A), Cys involved redox activity. Recent data using zebrafish    did affect ability proteins involved BER path-
Ape1 (zApe1) model demonstrates acquisition      way perform repair AP sites (Fig. 7B) using Cys65 human Ape1 converts redox-inactive zApe1         established BER-pathway assay (67). studies demon-
redox-active zApe1 (25). confirm  mutated         strate specificity E3330 redox, 
Cys65 human Ape1 Ala   performed cellular         pair function Ape1.
transactivation reporter analysis using AP-1 NF-B           additional approach demonstrate specificity downstream targets Ape1 (Fig. 4). Cys65        E3330 Ape1, used mutant zebrafish (T58C),
mutated Ala, Ape1 loses redox activity     converted redox-inactive Ape1 pro-
cell-based reporter  addition wild-type        tein redox-active protein (25), reacted E3330.
Ape1 results enhanced redox activity (Fig. 4), regardless     performed redox EMSA using AP-1 downstream target.                                        target protein. shown Fig. 8, E3330 blocked ability
   series experiments involved use small    T58C zebrafish Ape1, acquired redox
molecule redox inhibitor Ape1, 3-[5-(2,3-dimethoxy-6-         function, similar fashion blocks hu-




                                                                          FIG. 4. Effect human Ape1 Cys65 redox
                                                                          Ape1 mutant NF-    B AP-1 transactivation
                                                                          cell-based reporter assay  SKOV-3X
                                                                          cells transfected AP-1 NF-Bâ€“Luc 
                                                                          struct containing NF-B AP-1â€“response pro-
                                                                          moter driving expression luciferase
                                                                          gene. cells cotransfected plasmid
                                                                          pcDNAâ€“wild-type hApe1 redox mutant
                                                                          (pcDNA-C65A) Renilla luciferase control 
                                                                          porter vector pRL-CMV. 24-h transfection
                                                                          period, cells lysed, Firefly Renilla lu-
                                                                          ciferase activities assayed using Renilla lu-
                                                                          ciferase activity normalization. trans-
                                                                          fection experiments performed triplicate
                                                                          repeated 3 times independent ex-
                                                                          periments. Data expressed mean  standard
                                                                          error representative experiment, Stu-
                                                                          dentâ€™s t tests performed. *Significant differ-
                                                                          ence p  0.05 level comparing Cys65 mu-
                                                                          tant wt-Ape1 wt-Ape1 mock                                                                           pcDNA.
 REDOX ROLE APE1 CANCER ENDOTHELIAL CELLS                                                                      1859




FIG. 5. Synthesis 3-[5-(2,3-dimethoxy-6-
methyl-1,4-benzoquinoyl)]-2-nonyl-2-propi-
onic acid (E3330) using novel approach.




man Ape1 redox activity. concentration E3330          cancer cell lines, Hey-C2 SKOV-3X, pNF-
quired inhibit 50  redox activity 6.5 M      B-Luc pAP-1-Luc constructs Renilla luciferase 
wild-type hApe1 5 M T58C zApe.            porter vector pRL-CMV control transfection. conclusive, data demonstrate E3330 affect-    transfection, treated cells increasing amounts ing cysteines Ape1 proteins       E3330. observed Fig. 9, increasing amounts E3330
Cys65 human Ape1 primary target E3330      causes analogous decrease AP-1 main cysteine involved redox function Ape1.      NF-B activation, evidenced decrease confirmed studies mutated       AP-1 NF-B activation luciferase reporter gene.
cysteine human Ape1 individually, Cys65         results indicate decreased binding proteins major effect redox function Ape1 (data    blockage conversion oxidized shown). Experiments progress demonstrate           reduced state Ape1 E3330 blocking Ape1 
equivocally interaction E3330 Ape1 protein       dox function. mechanism involved (Georgiadis Kelley, personal            E3330 does affect repair functions Ape1,
communication, 2008).                                           shown Fig. 7, tested effect blocking Ape1 
  confirm activity E3330 Ape1 redox     dox function ovarian cancer cell lines. shown inhibitor cell-based assays, transfected ovarian   Fig. 10, E3330 causes decrease cell pro-




FIG. 6. EMSA studies AP-1 HIF-1  binding E3330
treatments. Increasing levels E3330 decrease purified c-Jun
binding vitro   SKOV-
3X ovarian cancer cells treated E3330 (B). HIF-1 downstream target redox
function Ape1, inhibition Ape1 redox E3330 blocks
HIF-1 binding (C). (D) West-
ern blot analysis samples (B) using Ape1 AP-1
antibodies, demonstrating level Ape1 AP-1 cell extracts identical, results observed decrease respective
proteins.
 1860                                                                                                                 LUO ET AL.




FIG. 7. Oligonucleotide gel-based endonuclease BER assays. Analysis performed described Methods (20,
41).   nanogram purified Ape1 protein used increasing E3330, indicated gel
lanes. Ape1 protein extracts added reaction mixture containing 0.2 pmol HEX-labeled double-stranded tetrahy-
drofuran oligonucleotide, 50 mM HEPES, 50 mM KCl, 10 mM MgCl2, 2 mM DTT, 1  BSA, 0.05  Triton X-100 (pH
7.5). Reactions E3330 incubated 15 min 37Â°C. Reactions halted adding 10 l 
mamide. Ape1 assay products separated 20  polyacrylamide gel containing 7 M urea. upper band (26-mer)
represents uncleaved AP oligonucleotides, lower band (14-mer) reacted oligonucleotide. (B) BER path-
way vitro analysis using gap-filling assay, described Singhal et al. (67). gap-filling assay initiated uracil oligonucleotide substrate, removed using uracil-glycosylase. BER pathway fully func-
tional, 48-mer band observed gel, 21-mer band indicates incomplete BER-pathway activity. E3330 added reactions, indicated, effect pathway, indicating effect Ape1-repair function.


liferation increasing amounts drug cell lines        simple highly reproducible method quantifying IC50 33 37 M, respectively. observed              cell proliferation used determine effect similar results cancer cell lines (data shown).       E3330 proliferation rate RVECs. shown Fig. results indicate redox activity functions          11A, addition E3330 inhibited RVEC growth dose 
Ape1 growth survival response cancer cells          pendent manner. Supplement bFGF basal media independent DNA repair activity Ape1.             significantly boosted proliferation rate.  sim-
findings confirm similar findings observed hemato-           ilar inhibition effect evident various doses poietic model embryonic stem cells (82). mecha-           E3330 treatments. difference E3330-treated
nistic studies occurring currently       group corresponding vehicle control way, preliminary studies indicate redox-           medium statistically significant (p  0.01).
inhibitory effect necessarily cell killing,        vitro angiogenesis assay used determine block cell proliferation cytostatic effect similar   effect E3330 RVEC formation capillary-like struc-
observed using Ape1 siRNA vivo (19, 20).                       tures Matrigel. inhibition effect E3330 similar
                                                                     proliferation assay lower dose range
                                                                     (Fig. 11B). E3330 1 M sufficient elicit 30  
E3330 inhibits RVEC proliferation                                                                      duction tube formation. Quantitative measurement angiogenesis vitro
                                                                     number tube units revealed difference sta-
  Proliferation endothelial cells (ECs) important        tistically significant (p  0.05). tube formation com-
dex angiogenic ability EC vitro. MTS assay         pletely abolished 5 M higher concentration.
 REDOX ROLE APE1 CANCER ENDOTHELIAL CELLS                                                                                 1861

                                                                    DNA-repair enzymes, including MGMT, polyADP-ribose
                                                                    polymerase (PARP1), ataxiaâ€“telangiectasia mutated kinase
                                                                    (ATM kinase), Ape1, DNA PKcs varying degrees                                                                     success development (12, 21, 48).
                                                                       goal developing inhibitors Ape1 po-
                                                                    tential cancer therapeutic, developing specific, 
                                                                    dependent inhibitors major functions Ape1
                                                                    (redox repair), focused blocking Ape1
                                                                    redox function. overwhelming evidence supports
                                                                    observation Cys65 main cysteine involved                                                                     redox role human Ape1, confirm                                                                     premise site-directed mutagenesis Cys65 site,
                                                                    leading lack NF-B AP-1 transactivation cell-
                                                                    model (Fig. 4) inhibition Ape1 redox 
                                                                    ing small moleculeâ€“specific inhibitor, E3330 (Figs. 6 9).
                                                                    Furthermore, demonstrate humanized zebrafish
                                                                    Ape1, previously demonstrated gained redox ac-
                                                                    tivity (25), inhibited E3330 (Fig. 8). addition,                                                                     redox inhibition Ape1 effect repair function
FIG. 8. Redox EMSA showing E3330 inhibition mutant               Ape1, demonstrated lack inhibition sep-
zebrafish Ape1. increasing E3330 incu-             arate DNA-repair assays (Fig. 7). E3330 able block
bated 2 l purified hApe1(lanes 1â€“7) mutant ze-             redox function Ape1 ovarian cancer cell lines
brafish Ape1 (T58C-zApe1) (lanes 8â€“13; reduced 1.0
                                                                    using transactivation reporter assay dose-depen-
mM DTT diluted 2 g/l 0.2 mM DTT PBS) EMSA reaction buffer [10 mM Tris (pH 7.5), 50 mM            dent manner (Fig. 9). data support cellular role NaCl, 1 mM MgCl2, 1 mM EDTA, 5  (vol/vol) glycerol]                 Ape1 redox activation downstream targets dem- total volume 10 l 30 min, EMSA          onstrate E3330 small molecule block transcription-fac-
assay performed. E3330 inhibited AP1-DNA bind-              tor activation; particularly transcription factors 
ing stimulated hApe1 T58C-zApe1 ex-              volved cancer cell growth proliferation, tent. Lane 1 unreduced hApe1 control; lane 2 control      NF-B, AP-1, HIF-1. data line DTT carryover, lane 13 unreduced T58C-zApe1              previous findings demonstrating blocking redox, trol. Lanes 3â€“7 human Ape1 reacted increasing          repair function Ape1 led blocking cell proliferation
amounts E3330. Lanes 8â€“12 T58C zebrafish Ape1            (82). previous studies demonstrated altering
acted increasing amounts E3330.                             Ape1 levels leads blockage cell growth increased
                                                                    cancer cell sensitivity (2, 6, 16, 19, 20, 30, 33, 37, 43â€“47, 51,
                                                                    59, 68, 70, 73â€“75, 81), studies used overexpression                                                                     Ape1, Ape1 antisense oligonucleotides, Ape1 siRNA:    results demonstrate inhibition redox activ-
                                                                    quandary approach, valid, ity significantly attenuates RVEC proliferation capillary
                                                                    approaches changes total cellular content level formation vitro. capillary formation RVECs appears
                                                                    Ape1 removes Ape1 functions, just  sensitive redox inhibition.
                                                                    pair redox activities. Ape multiple functions
                                                                    proteinâ€“protein interactions DNA 
Discussion
                                                                    pair signaling proteins, increase decrease Ape1
   long recognized DNA-damaging agents             protein result prejudiced inexact results. Use useful killing cancer cells mainstay    specific small-molecule inhibitors E3330 im-
cancer treatments (31, 49).  significant problem          portant delineate true role Ape1 various cancer, success DNA-damaging agents upregula-            disease, normal cellular functions. Ultimately, using
tion activation number different pathways       Ape1 redox inhibitors Ape1-specific endonuclease 
fer resistance cancer cells treatment DNA-       pair inhibitors clearer picture multiple ac-
damaging agents. includes pathways               tivites Ape1.
involved signaling, multidrug resistance, cell-cycle check-         goal developing specific Ape1 redox inhibi-
points, antiangiogenesis, potential approaches        tion study role Ape1 normal cancer cells, treat kill cancer. work focused block-      performed single-agent doseâ€“response studies using E3330
ing ability cancer cell recognize repair        ovarian cancer cell lines determined E3330 does
damaged DNA results line cancer treatments          single-agent cancer cell killing abilities (Fig. 10). 
(chemotherapy radiation). systems includes         ing restricted just ovarian cancer cell lines DNA-repair enzymes, Ape1, leading resistance             observed cell lines representing colon, lung, breast, brain, failure agent kill cancer cells (16, 21).   pancreatic, prostate, multiple myeloma cancers (data findings suggest possible strategy preventing       shown). contrast, significant growth inhibi-
sistance improving efficacy DNA-targeting agents         tion studies normal cells, hematopoietic em- inhibit DNA-repair enzyme responsible           bryonic cells (82), RVEC (Fig. 11) E3330 inhibits RVEC cell
resistance. potential recognized, evidenced        growth (MTS assay results). Additionally, identification small-molecule inhibitors       cell killing human CD34 progenitor cells (unpublished
 FIG. 9. Effect E3330 Ape1 redox transactivation assay. Effect E3330 endogenous cellular Ape1 redox ac-
tivity using functional transactivation assay described Methods Fig. 4. Increasing amounts E3330 added Hey-C2 SKOV-3X ovarian cancer cell lines. 24 h transfection, ratio firefly luciferase activ-
ity Renilla luciferase activity determined measure AP-1 NF-B activity. Data expressed mean  SEM independent experiments performed triplicate presented percentage transactivation compared normalized control E3330.
 REDOX ROLE APE1 CANCER ENDOTHELIAL CELLS                                                                             1863




FIG. 10. Cell-growth assay using E3330 ovarian cancer cell lines. MTT growth/survival assay 
formed described Methods. Increasing amounts E3330 resulted decreasing cell growth decreased cell num-
bers. Data expressed mean  SEM independent experiments performed triplicate.



data). data novel implicate redox role     tion using E3330 blocks RVEC cell growth, Ape cancer, â€œnormalâ€? cell survival. impli-      bFGF stimulation (Fig. 11). Additional studies using RVEC
cates redox role independent Ape1 DNA-repair            formation capillary-like structures Matrigel resulted function independent addition DNA-damaging              decreased angiogenesis, measured assay, agents. supported recently published data           lower dose range MTS assays (Fig. 11).
ovarian cancer studies xenografts, demonstrating          results demonstrate inhibition redox activity
knockdown Ape1 results blocking cell growth          significantly attenuates RVEC proliferation capillary 
proliferation, cell death (19). time    mation vitro, does cause cell death. Furthermore,
cer cell killing reported using small-molecule       capillary formation RVECs appears sen-
hibitor Ape1 redox function.                                       sitive redox inhibition Ape1 proliferation.    exciting results presented details        time role Ape1 clearly demon-
potential role Ape1 angiogenesis (Fig. 11). demon-           strated, necessitated use specific small-mole-
strated RVEC studies, inhibition Ape1 redox func-           cule Ape1 redox inhibitor identify novel activity.




FIG. 11. Inhibition redox activity Ape1 reduces retinal vascular endothelial cell angiogenesis vitro.   MTS proliferation assay, RVECs treated bFGF various doses E3330 (10â€“100 M) culture 2 days. dose-dependent inhibition RVEC growth evident basal media (EBM) bFGF-sup-
plemented (10 ng/ml) media (EBM  bFGF). number viable cells E3330-treated groups significantly dif-
ferent (p  0.01) corresponding vehicle control cells medium. (B) tube-formation assay, RVECs
cultured bFGF medium Matrigel treated various doses E3330 (1â€“20 M) 1 day. RVEC formation capillary-like structure significantly inhibited lower dose range. 30  reduction tube units 1 M
E3330 statistically different vehicle control (p  0.05).
 1864                                                                                                               LUO ET AL.

   discussed, Ape1 originally identified pri-      tetrahydrofuran; TMZ, temozolomide; XRCC1, x-ray cross
mary target E3330. E3330 immobilized beads,        complementing 1.
Ape1 identified nuclear extract Jurkat cells protein specifically binds E3330. using sur-
face plasmon resonance, kinetic constant (KD) 1.6 nM        References obtained binding E3330 Ape1, suggesting specific interaction. shown E3330           1. Bhakat KK, Izumi T, Yang SH, Hazra TK, Mitra S. Role
blocked ability Ape1 reduce NF-B, interfer-          acetylated human AP-endonuclease (APE1/Ref-1) reg-
ing redox activity Ape1 (27, 35, 52, 65).        ulation parathyroid hormone gene. EMBO J 22: series N- C-terminal truncation mutants, peptide          6299â€“6309, 2003.
                                                                  2. Bobola MS, Finn LS, Ellenbogen RG, Geyer JR, Berger MS,
including residues 72-88 Ape1 proposed bind                                                                      Braga JM, Meade EH, Gross  Silber JR. Apurinic/
E3330, suggesting E3330 interacts specific site
                                                                     apyrimidinic endonuclease activity associated  Ape1 (34, 54, 65).  believe ap-
                                                                     sponse radiation chemotherapy medulloblastoma
proach imperfect, truncated Ape1 molecules           primitive neuroectodermal tumors. Clin Cancer Res 11: unlikely fold correctly, identification       7405â€“7414, 2005. binding site suspect. addition, proposed bind-      3. Brimble MA, McEwan JF, Turner P. Asymmetric Diels-
ing site somewhat puzzling light structure           Alder addition cyclopentadiene chiral naphtho-
Ape1, obvious binding site noted (data              quinones tetrahedron. Asymmetry 9: 1239â€“1255, 1998.
shown). residues (aa 72â€“80) form ridge sur-        4. Campalans  Marsin S, Nakabeppu Y, Oâ€™Connor TR, Boi-
face molecule obvious cavities binding             teux S, Radicella JP. XRCC1 interactions multiple
pockets sufficiently large bind E3330. Currently,        DNA glycosylases: model recruitment base exci- pursuing studies delineate binding site          sion repair. DNA Repair (Amst) 4: 826â€“835, 2005.
gion E3330 Ape1.                                            5. Chakravarti  Delaney MA, Noll E, Black PM, Loeffler JS,
   conclusion, Ape1 multifunctional protein        Muzikansky  Dyson NJ. Prognostic pathologic
important DNA-repair redox capabilities.              significance quantitative protein expression profiling delineate various functions Ape1, small-molecule           human gliomas. Clin Cancer Res 7: 2387â€“2395, 2001.
hibitors function necessary ultimately     6. Chen DS Olkowski ZL. Biological responses human
clude function required normal cancer cell           apurinic endonuclease radiation-induced DNA damage.
function. Additionally, data demonstrate              Ann NY Acad Sci 726: 306â€“308, 1994.
new role Ape1 involvement angiogenesis,        7. Chou KM Cheng YC. exonuclease activity hu-
subsequent inhibition Ape1s redox function abrogates         man apurinic/apyrimidinic endonuclease (APE1): biochem-
                                                                     ical properties inhibition natural dinucleotide
role. use E3330 new analogues currently                                                                      Gp4G. J Biol Chem 278: 18289â€“18296, 2003.
development critical reagents future studies                                                                   8. Chou KM Cheng YC. exonucleolytic activity hu- cellular functions Ape1 potential therapeu-
                                                                     man apurinic/apyrimidinic endonuclease 3 mispaired
tic applications.                                                    DNA. Nature 415: 655â€“659, 2002.
                                                                  9. Chou KM, Kukhanova M, Cheng YC. novel action Acknowledgments                                                      human apurinic/apyrimidinic endonuclease: excision L-
   Financial support work provided               configuration deoxyribonucleoside analogs 3 ter-
National Institutes Health, National Cancer Institute             mini DNA. J Biol Chem 275: 31009â€“31015, 2000.
CA94025, CA106298, CA114571, CA121168 M.R.K. ,            10. Chou KM, Lam W, Cheng YC. novel DNA exonu-
                                                                     clease activity human apurinic/apyrimidinic endonucle-
CA 114571 M.M.G, IU Simon Cancer Center Translational
                                                                     ase (APE1): implication DNA mismatch repair. Proc initiative pilot funding (ITRAC) M.R.K. M.M.G.,                                                                      Assoc Ca Res 42: 2988, 2001. Riley Childrenâ€™s Foundation (M.R.K.). R.L.N. sup-
                                                                 11. Chung U, Igarashi T, Nishishita T, Iwanari H, Iwamatsu 
ported training grant 5T32CA009634.                               Suwa  Mimori T, Hata K, Ebisu S, Ogata E, Fujita T,                                                                      Okazaki T. interaction Ku antigen REF1
Abbreviations                                                        protein mediates negative gene regulation extracellular
   AP, apurinic/apyrimidinic; Ape1, AP endonuclease1;                calcium. J Biol Chem 271: 8593â€“8598, 1996.
ATM, ataxiaâ€“telangiectasia mutated; BER, base excision        12. Damia G Dâ€™Incalci M. Targeting DNA repair                                                                      promising approach cancer therapy. Eur J Cancer 43: 1791â€“
pair; CSB, Cockayne syndrome B; EC, endothelial cell;
                                                                     1801, 2007.
EMSA, electrophoretic mobility shift assay; FEN1, flap 
                                                                 13. Demple B Harrison L. Repair oxidative damage donuclease 1; GZMA, granzyme  HEX, 5 hexachloro-
                                                                     DNA: enzymology biology. Annu Rev Biochem 63:
fluorescein phosphoramidite;  incision repair; ITRAC,             915â€“948, 1994.
IU Simon Cancer Center Translational Research Accelera-          14. Dianova II, Bohr VA, Dianov GL. Interaction human
tion Collaboration; MMS, methylmethane sulfonate; NIR,               AP endonuclease 1 flap endonuclease 1 prolifer-
nucleotide incision repair; NK, natural killer; NMR, nu-             ating cell nuclear antigen involved long-patch base exci-
clear magnetic resonance;  nitric oxide; PARP1,                   sion repair. Biochemistry 40: 12639â€“12644, 2001.
polyADP-ribose polymerase 1; PCNA, proliferating cell            15. DiGiuseppe JA, Hunting DJ, Dresler SL. Aphidicolin-
nuclear antigen; PTEN, phosphatase tensin homo-                  sensitive DNA repair synthesis human fibroblasts dam-
logue; REC, retinal endothelial cell; redox, reduction oxy-          aged bleomycin distinct UV-induced repair.
genation; RVEC, retinal vascular endothelial cell; THF,              Carcinogen Carcinogenesis 11: 1021â€“1026, 1990.
 REDOX ROLE APE1 CANCER ENDOTHELIAL CELLS                                                                               1865

16. Evans AR, Limp-Foster M, Kelley MR. Going APE         32. Herring CJ, Deans B, Elder RH, Rafferty JA, MacKinnon J,
    ref-1. Mutat Res 461: 83â€“108, 2000.                                Barzilay G, Hickson ID, Hendry JH, Margison GP. Ex-
17. Fan  Beresford PJ, Zhang D, Xu  Novina CD, Yoshida             pression levels DNA repair enzyme HAP1 cor-
     Pommier Y, Lieberman J. Cleaving oxidative           relate radiosensitivities human HAP1-trans-
    pair protein Ape1 enhances cell death mediated                  fected rat cell lines. Br J Cancer 80: 940â€“945, 1999.
    granzyme  Nat Immunol 4: 145â€“153, 2003.                      33. Herring CJ, West CM, Wilks DP, Davidson SE, Hunter RD,
18. Fantini D, Vacotto C, Deganuto M, Bivi N, Gustincich S,            Berry P, Forster G, MacKinnon J, Rafferty JA, Elder RH,
    Marcon G, Quadrioglio FDG, Bhakat K, Mitra S.                  Hendry JH, Margison GP. Levels DNA repair
    APE1/Ref-1 regulates PTEN expression mediated Egr-1.            enzyme human apurinic/apyrimidinic endonuclease
    Free Radic Res 42: 20â€“29, 2008.                                    (APE1, APEX, Ref-1) associated intrinsic ra-
19. Fishel ML, Y, Reed  Chin-Sinex H, Hutchins GD,               diosensitivity cervical cancers. Br J Cancer 78: 1128â€“1133,
    Mendonca MS, Kelley MR. Knockdown DNA                1998.
    pair redox signaling protein Ape1/Ref-1 blocks ovarian     34. Hiramoto M, Shimizu N, Nishi T, Shima D, Aizawa S,
    cancer cell tumor growth. DNA Repair (Amst) 7:                 Tanaka H, Hatakeyama M, Kawaguchi H, Handa H.
    177â€“186, 2008.                                                     High-performance affinity beads identifying anti-NF-
20. Fishel ML, Y, Smith ML, Kelley MR. Manipulation             kappa B drug receptors. Methods Enzymol 353: 81â€“88, 2002.
    base excision repair sensitize ovarian cancer cells   35. Hiramoto M, Shimizu N, Sugimoto K, Tang J, Kawakami Y,
    alkylating agent temozolomide. Clin Cancer Res 13: 260â€“267,        Ito M, Aizawa S, Tanaka H, Makino  Handa H. Nu-
    2007.                                                              clear targeted suppression NF-kappa B activity 21. Fishel ML Kelley MR. DNA base excision repair              novel quinone derivative E3330. J Immunol 160: 810â€“819,
    protein Ape1/Ref-1 therapeutic chemopreventive            1998.
    target. Mol Aspects Med 28: 375â€“395, 2007.                     36. Hsieh MM, Hegde V, Kelley MR, Deutsch WA. Activa-
22. Flader C, Liu J, Borch RF. Development novel qui-           tion APE/Ref-1 redox activity mediated reactive
    phosphorodiamidate prodrugs targeted DT-di-                oxygen species PKC phosphorylation. Nucleic Acids Res
    aphorase. J Med Chem 43: 3157â€“3167, 2000.                          29: 3116â€“3122, 2001.
23. Flader C, Liu J, Borch RF. Development novel qui-       37. Ide H Kotera M. Human DNA glycosylases involved     phosphorodiamidate prodrugs targeted DT-di-                repair oxidatively damaged DNA. Biol Pharm Bull 27:
    aphorase. J Med Chem 43: 3157â€“3167, 2000.                          480â€“485, 2004.
24. Fung H Demple B. vital role Ape1/Ref1 protein        38. Jeon BH, Gupta G, Park YC, Qi B, Haile  Khanday FA, Liu
    repairing spontaneous DNA damage human cells. Mol            YX, Kim JM, Ozaki M, White AR, Berkowitz  Irani
    Cell 17: 463â€“470, 2005.                                            K. Apurinic/apyrmidinic endonuclease 1 regulates endo-
25. Georgiadis M, Luo M, Gaur R, Delaplane S, Li X, Kel-           thelial production vascular tone. Circ Res 95:
    ley M. Evolution redox function mammalian                902â€“910, 2004.
    apurinic/apyrimidinic. Mutat Res 2008.                         39. Jin  WS, Gao F, Flagg T, Deng X. Bcl2 suppresses
26. Gorman MA, Morera S, Rothwell DG, la Fortelle E, Mol            DNA repair enhancing c-Myc transcriptional activity. J
    CD, Tainer JA, Hickson ID, Freemont PS. crystal            Biol Chem 281: 14446â€“14456, 2006.
    structure human DNA repair endonuclease HAP1            40. Kelley MR, Hansen W, Xu Y, Yacoub  Williams D,     suggests recognition extra-helical deoxyribose DNA       Deutsch WA. Combining O6-methylguanine DNA methyl-
    abasic sites. EMBO J 16: 6548â€“6558, 1997.                          transferase (MGMT) AP endonuclease (APE) DNA 
27. Goto M, Yamada K, Katayama K, Tanaka  Inhibitory             pair activities chimeric proteins: use retroviral gene
    effect E3330, novel quinone derivative able sup-           therapy chemotherapeutic dose intensification. Proc     press tumor necrosis factor-alpha generation, activa-           Assoc Cancer Res 38: 383, 1997.
    tion nuclear factor-kappa B. Mol Pharmacol 49: 860â€“873,     41. Kreklau EL, Limp-Foster M, Liu N, Xu Y, Kelley MR,     1996.                                                              Erickson LC. novel fluorometric oligonucleotide assay 28. Hansen CA, Dean AB, Draths KM, Frost JW. Synthesis             measure O(6)-methylguanine DNA methyltransferase,
    1,2,3,4-tetrahydroxybenzene D-glucose: exploiting          methylpurine DNA glycosylase, 8-oxoguanine DNA glyco-
    myo-inositol precursor aromatic chemicals. J            sylase abasic endonuclease activities: DNA repair sta-
    Chem Soc 121: 3799â€“3800, 1999.                                     tus human breast carcinoma cells overexpressing
29. Hansen WK, Deutsch WA, Yacoub  Xu Y, Williams DA,                methylpurine DNA glycosylase. Nucleic Acids Res 29: 2558â€“
    Kelley MR. Creation fully functional human chi-           2566, 2001.
    meric DNA repair protein: combining O6-methylguanine           42. Kuninger DT, Izumi T, Papaconstantinou J, Mitra S. Hu-
    DNA methyltransferase (MGMT) AP endonuclease                   man AP-endonuclease 1 hnRNP-L interact     [APE/redox effector factor 1 (Ref 1)] DNA repair proteins.         nCaRE-like repressor element AP-endonuclease 1 pro-
    J Biol Chem 273: 756â€“762, 1998.                                    moter. Nucleic Acids Res 30: 823â€“829, 2002.
30. Harrison JF, Rinne ML, Kelley MR, Druzhyna NM, Wilson          43. Lau JP, Weatherdon KL, Skalski V, Hedley DW. Effects
    GL, LeDoux SP. Altering DNA base excision repair: use          gemcitabine APE/ref-1 endonuclease activity pan-
    nuclear mitochondrial-targeted N-methylpurine               creatic cancer cells, therapeutic potential antisense
    DNA glycosylase sensitize astroglia chemotherapeutic         oligonucleotides. Br J Cancer 91: 1166â€“1173, 2004.
    agents. Glia 55: 1416â€“1425, 2007.                              44. Liu L Gerson SL. Therapeutic impact methoxyamine:
31. Havelka  Berndtsson M, Olofsson MH, Shoshan MC,                 blocking repair abasic sites base excision repair
    Linder S. Mechanisms action DNA-damaging              pathway. Curr Opin Invest Drugs 5: 623â€“627, 2004.
    ticancer drugs treatment carcinomas: acute apopto-    45. Liu L, Nakatsuru Y, Gerson SL. Base excision repair     sis  targetâ€? effect? Mini Rev Med Chem 7: 1035â€“1039,        therapeutic target colon cancer. Clin Cancer Res 8:
    2007.                                                              2985â€“2991, 2002.
 1866                                                                                                                     LUO ET AL.

46. Liu L, Yan L, Donze JR, Gerson SL. Blockage abasic        63. Peddi SR, Chattopadhyay R, Naidu CV, Izumi T.     site repair enhances antitumor efficacy 1,3-bis-(2-               human apurinic/apyrimidinic endonuclease-1 suppresses
    chloroethyl)-1-nitrosourea colon tumor xenografts. Mol            activation poly(adp-ribose) polymerase-1 induced     Cancer Ther 2: 1061â€“1066, 2003.                                      DNA single strand breaks. Toxicology 224: 44â€“55, 2006.
47. Liu L, Yan L, Mahajan V, Donze JR, Gerson SL. Inhibition     64. Ranalli TA, Tom S, Bambara RA. AP endonuclease 1 
    AP site repair coupled action topoisomerase II poi-       ordinates flap endonuclease 1 DNA ligase activity     son: potential strategy enhance efficacy chemothera-         long patch base excision repair. J Biol Chem 277: 41715â€“41724,
    peutic alkylating agents. Proc Assoc Ca Res 44, 2003.             2002.
48. Madhusudan S Hickson  DNA repair inhibition: se-         65. Shimizu N, Sugimoto K, Tang J, Nishi T, Sato  Hiramoto
    lective tumour targeting strategy. Trends Mol Med 11:                M, Aizawa S, Hatakeyama M, Ohba R, Hatori H, Yoshikawa
    503â€“511, 2005.                                                       T, Suzuki F, Oomori  Tanaka H, Kawaguchi H, Watanabe
49. Martin F Solary E. Tumor cell resistance DNA-dam-             H, Handa H. High-performance affinity beads iden-
    aging agents: apoptosis neiosis. Curr Med Chem            tifying drug receptors. Nat Biotechnol 18: 877â€“881, 2000.
    ticancer Agents 4: 461â€“463, 2004.                                66. Sidorenko VS, Nevinsky GA, Zharkov  Mechanism
50. Martinvalet D, Zhu P, Lieberman J. Granzyme induces            interaction human 8-oxoguanine-DNA glycosy-
    caspase-independent mitochondrial damage, required           lase AP endonuclease. DNA Repair 6: 317â€“328, 2007.
    step apoptosis. Immunity 22: 355â€“370, 2005.                  67. Singhal RK, Prasad R, Wilson SH. DNA polymerase beta
51. McNeill DR Wilson DM 3rd. dominant-negative form               conducts gap-filling step uracil-initiated base excision
    major human abasic endonuclease enhances cellular             repair bovine testis nuclear extract. J Biol Chem 270:
    sensitivity laboratory clinical DNA-damaging agents.          949â€“957, 1995.
    Mol Cancer Res 5: 61â€“70, 2007.                                   68. Spitz DR, Azzam EI, Li JJ, Gius D. Metabolic oxida-
52. Miyamoto K, Nagakawa J, Hishinuma  Hirota K, Yasuda                tion/reduction reactions cellular responses ionizing
    M, Yamanaka T, Katayama K, Yamatsu  Suppressive                radiation: unifying concept stress response biology. 
    effects E3330, novel quinone derivative, tumor ne-           cer Metastasis Rev 23: 311â€“322, 2004.
    crosis factor-alpha generation monocytes macro-         69. Su X, Sorenson CM, Sheibani N. Isolation charac-
    phages. Agents Actions 37: 297â€“304, 1992.                            terization murine retinal endothelial cells. Mol Vis 9:
53. Nazarkina ZK, Khodyreva SN, Marsin S, Lavrik OI,                 171â€“178, 2003.
    Radicella JP. XRCC1 interactions base excision repair       70. Taverna P, Liu L, Hwang HS, Hanson AJ, Kinsella TJ,     DNA intermediates. DNA Repair (Amst) 6: 254â€“264, 2007.               Gerson SL. Methoxyamine potentiates DNA single strand
54. Nishi T, Shimizu N, Hiramoto M, Sato  Yamaguchi Y,                 breaks double strand breaks induced temozolomide
    Hasegawa M, Aizawa S, Tanaka H, Kataoka K, Watanabe                  colon cancer cells. Mutat Res 485: 2